ARGX-117

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

NeuropathyDelayed Graft Function

21 competitors in Neuropathy

#DrugCompanyPhaseTrials

1

Elavil

AstraZeneca

Approved

—2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

33

Accupril

Pfizer

Approved

14

Pamelor

SSpecgx

Approved

15

Mexitil

Boehringer Ingelheim

Approved

16

Epsom Salt

FFresenius Kabi USA, LLC

Approved

—7

Immunoglobulin

Sanofi

Phase 3

48

Rituxan

Roche

Phase 2

29

Calciferol

Jazz Pharmaceuticals

Phase 2

110

Calquence

AstraZeneca

Phase 2

1Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Neuropathy2 trials

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Active, not recruiting·Argenx·Phase 2·NCT05405361·51 enrolled

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Completed·Argenx·Phase 2·NCT05225675·54 enrolled

Delayed Graft Function1 trial

A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function

Active, not recruiting·Argenx·Phase 2·NCT05907096·103 enrolled

Unspecified1 trial

SAD and MAD Study With IV and SC Doses of ARGX-117

Completed·Argenx·Phase 1·NCT04532125·110 enrolled

Details

Drug Info

Related News